Scientists at Queen Mary University of London are using cutting-edge single-cell genomics to observe how cancer emerges by analyzing thousands of individual cells rather than population averages, revealing rare cell states and regulatory patterns invisible to traditional methods. This approach is transforming how researchers understand disease development and could eventually enable doctors to tailor treatments to each patient's unique genetic profile. What Are Single-Cell Genomics and Why Do They Matter? Genomics is the study of DNA and how it's regulated, essentially the instruction manual that tells cells what to do. For decades, researchers analyzed DNA from thousands or millions of cells mixed together, like trying to understand a crowd by looking at an average person. Single-cell genomics changes that equation entirely. The ETT lab at Queen Mary University of London, led by Dr. Elena Torlai Triglia, uses single-cell technologies to profile gene expression and DNA accessibility in thousands of individual cells simultaneously. This reveals what bulk methods cannot detect: rare cell states, subtle transitions between cell types, and new layers of genetic regulation that drive disease. The team combines molecular experiments with computational analysis to map the regulatory networks controlling how cells make decisions and respond to challenges. The practical impact is significant. When studying melanoma, a skin cancer characterized by a very high number of DNA sequence changes, single-cell approaches expose how cells transform as cancer develops. These insights could eventually help doctors predict which patients will develop aggressive tumors and which treatments will work best for their specific cancer genetics. How Are Researchers Using This Technology to Fight Cancer? - Melanoma Tracking: The ETT lab applies single-cell genomics to understand how cells change during melanoma development, capturing the genetic and regulatory shifts that traditional bulk sequencing methods miss entirely. - Regulatory Network Mapping: By combining molecular experiments with computational analysis, researchers create detailed maps of the genetic networks controlling cell behavior and disease progression. - Rare Cell Discovery: Single-cell methods identify uncommon cell states and subtle transitions that may hold the key to understanding why some cancers are more aggressive than others. The research has attracted significant institutional support. The ETT lab recently received a Springboard award from the Academy of Medical Sciences, recognizing the importance of this work. This funding reflects growing confidence that single-cell approaches represent a genuine breakthrough in understanding how diseases emerge at the molecular level. Why Is the UK Leading This Genomics Revolution? The United Kingdom holds a world-leading position in genomic research and its intersection with healthcare, building on decades of excellence in genetics and molecular biology. This leadership stems from several interconnected strengths: national biobanks that store genetic data from thousands of patients, large-scale genomic atlassing efforts that catalog how genes work across different tissues, and cutting-edge sequencing approaches combined with machine learning analytical methods. At Queen Mary University of London, genomics research spans multiple disciplines and research centers. The Centre for Evolutionary and Functional Genomics explores how genomes change across species and shape biological traits. The Centre for Epigenetics unites researchers studying how chemical and structural modifications of DNA influence development and disease. These centers collaborate with institutes like the Precision Healthcare University Research Institute (PHURI) and the Digital Environment Research Institute (DERI), which focus on large-scale patient cohorts and cutting-edge analytical expertise to inform data-driven clinical approaches. This institutional ecosystem creates a powerful advantage. Researchers can access large patient populations, combine experimental and computational expertise, and translate discoveries into clinical applications faster than isolated labs could achieve. The result is a research environment where fundamental discoveries about how cells work can quickly inform treatment strategies for real patients. What Does This Mean for Personalized Medicine? The ultimate goal of single-cell genomics research is personalized medicine: tailoring treatments to each patient's unique genetic and cellular profile. Understanding how genetics and epigenetics interact to shape gene activity is essential to achieving this vision. When doctors can read the genetic playbook of a patient's cancer at single-cell resolution, they gain the ability to predict treatment response and select therapies most likely to work. Students at Queen Mary University of London are already learning these techniques. Genomics is embedded throughout the Biomedical Sciences and Biology curricula, including modules on genetics, human genetic disorders, genes and bioinformatics, and functional genomics and epigenetics. The university also offers specialized postgraduate programs like the MSc in Bioinformatics and MSc in AI in Biosciences. Students have opportunities to join research projects in active laboratories, including the ETT lab, developing both experimental and computational skills essential for modern genomic research. This educational pipeline ensures that the next generation of researchers will be trained in single-cell methods and computational genomics from the start of their careers. As these techniques become more routine, the pace of discovery should accelerate, bringing personalized cancer treatments and other genomics-based therapies closer to clinical reality.
